Delivered 38% year-over-year net revenue growth, expanded into 14 new markets, and maintained a debt-free balance sheet with over EUR 200 million in cash. Recurring revenue rose 18%, and guidance for 2026 is reaffirmed, with multiple pipeline milestones expected by year-end.Based on Cosmo Pharmaceu…
Delivered 38% year-over-year net revenue growth, expanded into 14 new markets, and maintained a debt-free balance sheet with over EUR 200 million in cash. Recurring revenue rose 18%, and guidance for 2026 is reaffirmed, with multiple pipeline milestones expected by year-end.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.